Literature DB >> 35822318

Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review.

Yong Suk Jo1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammation characterized by fixed airflow limitation and chronic respiratory symptoms, such as cough, sputum, and dyspnea. COPD is a progressive disease characterized by a decline in lung function. During the natural course of the disease, acute deterioration of symptoms leading to hospital visits can occur and influence further disease progression and subsequent exacerbation. Moreover, COPD is not only restricted to pulmonary manifestations but can present with other systemic diseases as comorbidities or systemic manifestations, including lung cancer, cardiovascular disease, pulmonary hypertension, sarcopenia, and metabolic abnormalities. These pulmonary and extrapulmonary conditions lead to the aggravation of dyspnea, physical inactivity, decreased exercise capacity, functional decline, reduced quality of life, and increased mortality. In addition, pneumonia, which is attributed to both COPD itself and an adverse effect of treatment (especially the use of inhaled and/or systemic steroids), can occur and lead to further deterioration in the prognosis of COPD. This review summarizes the long-term outcomes of patients with COPD. In addition, recent studies on the prediction of adverse outcomes are summarized in the last part of the review.

Entities:  

Keywords:  Chronic Obstructive Pulmonary Disease; Exacerbation; Lung Function; Mortality; Outcome

Year:  2022        PMID: 35822318      PMCID: PMC9537656          DOI: 10.4046/trd.2022.0074

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  65 in total

1.  Relationship between FEV1 reduction and respiratory symptoms in the general population.

Authors:  N Jakeways; T McKeever; S A Lewis; S T Weiss; J Britton
Journal:  Eur Respir J       Date:  2003-04       Impact factor: 16.671

2.  The natural history of community-acquired pneumonia in COPD patients: a population database analysis.

Authors:  Hana Müllerova; Chuba Chigbo; Gerry W Hagan; Mark A Woodhead; Marc Miravitlles; Kourtney J Davis; Jadwiga A Wedzicha
Journal:  Respir Med       Date:  2012-05-22       Impact factor: 3.415

3.  Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Xuesong Chen; Shaowen Tang; Kouying Liu; Qinling Li; Hui Kong; Xiaoning Zeng; Weiping Xie; Hong Wang
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

4.  Pulmonary arterial enlargement and acute exacerbations of COPD.

Authors:  J Michael Wells; George R Washko; MeiLan K Han; Naseer Abbas; Hrudaya Nath; A James Mamary; Elizabeth Regan; William C Bailey; Fernando J Martinez; Elizabeth Westfall; Terri H Beaty; Douglas Curran-Everett; Jeffrey L Curtis; John E Hokanson; David A Lynch; Barry J Make; James D Crapo; Edwin K Silverman; Russell P Bowler; Mark T Dransfield
Journal:  N Engl J Med       Date:  2012-09-03       Impact factor: 91.245

Review 5.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

6.  Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Giuseppe Valerio; Pierluigi Bracciale; Anna Grazia D'Agostino
Journal:  Ther Adv Respir Dis       Date:  2009-02       Impact factor: 4.031

7.  Features of COPD as Predictors of Lung Cancer.

Authors:  Laurie L Carr; Sean Jacobson; David A Lynch; Marilyn G Foreman; Eric L Flenaugh; Craig P Hersh; Frank C Sciurba; David O Wilson; Jessica C Sieren; Patrick Mulhall; Victor Kim; C Matthew Kinsey; Russell P Bowler
Journal:  Chest       Date:  2018-02-13       Impact factor: 9.410

8.  Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation.

Authors:  Sarah E Jones; Matthew Maddocks; Samantha S C Kon; Jane L Canavan; Claire M Nolan; Amy L Clark; Michael I Polkey; William D-C Man
Journal:  Thorax       Date:  2015-01-05       Impact factor: 9.139

Review 9.  Updated Perspectives on Pulmonary Hypertension in COPD.

Authors:  Isabel Blanco; Olga Tura-Ceide; Victor Ivo Peinado; Joan Albert Barberà
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-09

10.  Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials.

Authors:  Lei Pan; Manyuan Wang; Xiaomei Xie; Changjun Du; Yongzhong Guo
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.